WORKING TOGETHER FOR BRIGHT FUTURES

CAC2 ANNUAL SUMMIT
NATIONWIDE CHILDREN’S HOSPITAL
JUNE 18 – 20, 2019
Opening New Doors to Cancer Care

Every 35 minutes, a new child receives a pediatric cancer diagnosis in the United States. And 60% of children who survive cancer suffer late-effects, including infertility, heart failure or secondary cancers. Pediatric cancer research receives just 4% of the federally-funded annual budget from the National Cancer Institute.

Because of statistics like these, the Division of Hematology, Oncology & Blood and Marrow Transplant at Nationwide Children’s Hospital is dedicated to making significant, lasting progress on every front in the fight against pediatric cancer. As one of the top ranked U.S. News and World Report pediatric cancer programs, we understand the value of collaborating with organizations like the Coalition Against Childhood Cancer.

While more children than ever before are surviving childhood cancer, we will not rest until there’s a cure for every patient – and survivors have the quality of life they deserve. We are proud to be on the forefront of care in each step of a patient’s journey.

We are leaders of the NEXT Consortium, which brings together more than 40 institutions internationally to find solutions for medulloblastoma that won’t have devastating neurological effects on patients.

We are recipients of a $6.2 million Moonshot Grant from The National Cancer Institute at the National Institutes of Health to help uncover how proteins produced by a mutated gene transform healthy cells into tumor cells causing Ewing sarcoma.

We have built a comprehensive cellular therapies program, which was selected as a certified treatment center for Kymriah™ and recipients of the first grant awarded from the Department of Defense for investigating the application of cellular therapies in patients with neuroblastoma.

We have a robust Psychosocial Services program that helps children return to a new state of normal following their treatment, with a focus on the physical, mental and emotional needs of each patient and family.

Thank you for joining us at Nationwide Children’s Hospital to discuss the future of pediatric cancer care.
NATIONWIDE CHILDREN’S WELCOMES YOU

It is a great honor for Nationwide Children’s Hospital to host the Coalition Against Childhood Cancer (CAC2) 2019 Annual Summit as we work together toward a better future for pediatric cancer patients everywhere.

At Nationwide Children’s, we are driven to achieve the best possible outcome for every patient, even those who never come to our campus. We aggressively support the discovery of new knowledge to improve child health and well-being, through advanced research, advocacy and clinical care. The Abigail Wexner Research Institute is seamlessly integrated with our clinical programs to speed the translation of research from bench to bedside.

We are proud to host an organization that holds the values of collaboration, information exchange, and community as highly as we do here at Nationwide Children’s.

On behalf of the clinicians, researchers and staff at Nationwide Children’s Hospital and the Abigail Wexner Research Institute, thank you for you joining us here in Columbus, Ohio, to share knowledge, experiences and ideas, and to learn from leaders in the fields of research, clinical care and advocacy. We look forward to supporting you now and in the future in our collective mission to provide the best possible outcomes for families affected by pediatric cancer.

John A. Barnard, MD
Chair of Pediatrics
President of the Abigail Wexner Research Institute
@johnbarnardmd

Timothy P. Cripe, MD, PhD
Division Chief, Hematology Oncology and Bone & Marrow Transplant
@KidsOncDoc
Our Mission
CAC2 fosters and sustains greater levels of collaboration, information exchange, and learning across the childhood cancer community through agreed upon initiatives in the areas of advocacy and awareness building, family support, and research and treatment.

Our Origins and Vision
The founders of CAC2 first met together in 2011 to explore ways the community could work together to raise awareness and collaborate, without duplicating the efforts of existing organizations. This grassroots movement brought together representatives of small, medium-sized, and large organizations and committed individuals who fight childhood cancer and provide support to the children and families affected by the disease. The hope was that by working together we could bridge some of the natural fragmentation that arises from having a diverse community of passionate advocates.

Much of the strength of the community comes from the many different groups and individuals who have joined the fight. However, with greater cooperation among participants, more coordinated action, and higher levels of collaboration, we can make more progress, faster. CAC2 hopes the childhood cancer community will benefit from greater levels of coordinated action that:

(1) leverage the unique strengths of the members
(2) minimize waste of precious resources and expertise
(3) drive better outcomes for patients and their families

The primary values underlying CAC2 are to put the children and their families first in everything we do and to support organizations active in the fight against childhood cancer. We will support, not compete with, our member organizations and the childhood cancer community through action-oriented, member-directed projects.
Welcome to the 2019 CAC2 Summit!

Dear Members, Speakers, and Guests,

On behalf of the Coalition Against Childhood Cancer, our venue host Nationwide Children’s Hospital, our presenting sponsor Novartis, and our other generous sponsors and supporters, welcome to the 2019 CAC2 Summit. This year our program highlights the many ways we and our partners in the community can build a brighter future for children and adolescents with cancer and their families. We look forward to forging new relationships, strengthening existing ties, and learning from one another in a robust and energized setting.

A major goal of this meeting – and an overarching goal of CAC2 – is to provide a conduit for information exchange among various stakeholders in the childhood cancer community. We hope that through a series of talks and panels we can highlight opportunities for us to work together. We also strive to encourage further collaboration that can speed the process of bringing life-saving treatments and care to pediatric cancer patients and prioritize access to the best that science has to offer on behalf of these children and adolescents.

Over the next two days, we encourage you to take full advantage of the rich programming and abundance of networking opportunities. Dr. Timothy Cripe will set the tone for our first day by highlighting how immunologic therapies hold promise for greater safety and better outcomes for children and teens with cancer. Our morning panelists will help us understand why this goal is crucially important, as we listen and engage in their discussion of the physical and psychosocial burdens borne by the survivors of our current treatment protocols. After lunch, we will turn to another critical part of the equation. The physician-scientists in our afternoon panel will shed light on both the progress and the hurdles they encounter trying to build better frontline treatment options. We will also welcome other speakers throughout the day who will help us hone our understanding of the opportunities we have to shape the future of pediatric cancer.

Our sessions on Thursday provide members with multiple chances to reflect on what they have heard and to build a work plan for our next year together. We have adapted the World Café process to give each participant a voice in shaping CAC2’s 2019-20 Interest Group initiatives. During the members’ business meeting, we will receive the interest group report-outs and set our agenda and leadership for the coming year.

Thank you for helping us affirm our primary shared value “to put children with cancer and their families first in all that we do.” Please make the most of this opportunity, embrace the collaborative spirit, and be inspired to action!

With great appreciation,

Vickie Buenger
President
Coalition Against Childhood Cancer (CAC2)
Let’s imagine our future together working for a world without childhood cancers.
Day One: Wednesday, June 19, 2019

Location for All Day One Sessions:
Nationwide Children’s Hospital
Stecker Auditorium
Ann Isaly Wolfe Education Building
575 S 18th Street
Columbus, OH 43205

8:00 am – 8:30 am
BREAKFAST AND GATHERING

8:30 am – 8:45 am
WELCOME AND OPENING REMARKS
John Barnard, MD
Nationwide Children’s Hospital; The Ohio State University College of Medicine

8:45 am – 9:30 am
New Immunologic Therapies for Childhood Cancer: Towards a Better and Safer World
Timothy Cripe, MD, PhD, FAAP
Nationwide Children’s Hospital; The Ohio State University College of Medicine

9:30 am – 10:00 am
Non-Trial Access to Investigational Drugs: Updates & Unresolved Issues
Lisa Kearns, MS, MA
New York University School of Medicine, Division of Medical Ethics

10:00 am – 10:15 am
MORNING COFFEE BREAK AND NETWORKING

10:15 am – 11:45 am
A Conversation about Childhood Cancer Survivorship
Moderator: Mariah Forster Olson, MBA
Neuroblastoma Children’s Cancer Society

Panelists:
Amelia Baffa, MSN, APRN, PMHNP-BC
UH Rainbow Babies & Children’s Hospital

Greg Aune, MD, PhD
Greehey Children’s Cancer Research Institute
LUNCH and GROUP PHOTO
11:45 am – 12:45 pm

12:45 pm – 2:30 pm
A Conversation about Progress and Hurdles to Better Frontline Treatment Options
Moderator: Vickie Buenger, PhD
Coalition Against Childhood Cancer

Panelists:
Peter Adamson, MD
Children’s Oncology Group; Perelman School of Medicine, University of Pennsylvania; Children’s Hospital of Philadelphia

Steve DuBois, MD, MS
Harvard Medical School; Dana-Farber / Boston Children’s Cancer and Blood Disorders Center

Lucas Moreno Martin Retortillo, MD, PhD
Hospital Infantil Universitario Niño Jesus

2:30 pm – 2:45 pm
AFTERNOON COFFEE BREAK AND NETWORKING

2:45 pm – 3:30 pm
Biobanking in the Context of Cancer Clinical Trials
Nilsa Ramirez, MD
Nationwide Children’s Hospital; The Ohio State University College of Medicine; The OSU Comprehensive Cancer Center

3:30 pm - 4:00 pm
Data Sharing and Gabriella Miller Kids First
Adam Resnick, PhD
Children’s Hospital of Philadelphia

4:00 pm – 4:15 pm
AFTERNOON COFFEE BREAK AND NETWORKING

4:15 pm - 5:00 pm
Psychosocial Impact of Pediatric Cancer on Families
Cynthia Gerhardt, PhD
Nationwide Children’s Hospital; The Ohio State University

5:00 pm – 7:00 pm
RECEPTION
Immediately following
Day Two: Thursday, June 20, 2019

8:00 am – 9:00 am  
Room 025A  
WELCOME PLENARY SESSION, WITH CONTINENTAL BREAKFAST

9:00 am – 10:30 am  
WORLD CAFÉ

WHAT IS WORLD CAFÉ?  
World Café is an exploratory method that uses rotating small-group conversations to finesse thought in search of progress and common ideas. We will use this proven technique to pull out the ideas and topics that our members care about and want to work on together in the next year.

WHAT OUTPUT IS WORLD CAFÉ DESIGNED TO DELIVER?  
World Café is designed to give voice to CAC2 members around the issues that matter to them, aligning on themes to serve as primary input to our Interest Group Breakout sessions at the 2019 CAC2 Annual Summit.

HOW IT WORKS  
World Café will feature several small cafe-style tables within each topic area. CAC2 members will rotate through the conversational groupings 3 times to maximize interactions and idea generation. You can sample a new topic area during each rotation, or you can choose to focus on the same topic area for each turn.

At the conclusion of the World Café, we will break into Interest Groups to pursue action plans in support of the best ideas flowing from the process. This will allow us to move directly from discussions to actions, so by the end of the day we will have identified viable projects and attached names and dates to move forward with clear accountabilities.

Three broad questions will inform our conversations:
• **Advocacy and Awareness:** CAC2 aims to foster collaboration without creating competition. What are some specific strategies that would enable our community to have a more unified and impactful voice in the arena of Advocacy and Awareness?
• **Family Support and Survivorship:** How can CAC2 and the survivorship interest group address the needs and wants, and provide information and resources to childhood and adolescent cancer survivors and their families?
• **Research and Treatment:** Given your experience with collaborative fundraising and joint funding of projects and your own plans for funding research over the next year, how can CAC2 encourage/facilitate members to collaboratively fund research?

10:30 am – 10:45 am  
MORNING COFFEE BREAK AND NETWORKING

10:45 am – 1:30 pm  
Main Auditorium, Room 131, and Room 137  
INTEREST GROUP BREAKOUT SESSIONS WITH WORKING LUNCH
• Advocacy and Awareness  
• Family Support and Survivorship  
• Research and Treatment

1:30 pm – 2:30 pm  
Room 025A  
CLOSING SESSION, WORKING GROUP REPORT OUTS
2:30 pm – 4:00 pm
TOURS (Two Options)

1) The Institute for Genomic Medicine and Good Manufacturing Practices Facility
Tour hosts: Dr. Rick Wilson, Executive Director of IGM and Elena Chiappinelli, Administrative Director of IGM and Dr. Jeffery Auletta, Section Chief of BMT and Dr. Dean Lee, Director of Cell Therapies

Led by co-executive Directors Elaine Mardis, PhD, and Rick Wilson, PhD, The Institute for Genomic Medicine (IGM) combines a robust clinical laboratory with genomic scientists and clinical geneticists to optimize patient care. Collaboration among clinicians, physician-scientists and basic science investigators enables the team to quickly transition novel research into advanced diagnostics, using state-of-the-art technology.

The IGM’s world-renowned faculty are moving genome-based testing into the mainstream of pediatric diagnosis and treatment, making the results accessible and meaningful for patients and families. Through the Cancer Protocol, developed with the Division of Hematology, Oncology & Blood and Marrow Transplant, patients with recurrent or resistant cancers are offered a full genomic analysis of tumor and normal cells for insights into what is driving the cancer.

The Research Institute at Nationwide Children’s Hospital is the home to a current Good Manufacturing Practices (cGMP) Clinical Manufacturing Facility that operates according to FDA cGMP Guidelines to ensure the safety of manufactured biologic products. The facility leaders use knowledge, resources, technology, and experience in the field of translational and regulatory science, in collaboration with our clients, to develop new, safe, and effective long-term treatments for diseases. The facility’s production capabilities have allowed us to open a number of cellular therapy trials over the last year.

The first of its kind at a pediatric institution, the 9000-square foot clinical manufacturing facility space is comprised of clean room suites, a quality control lab and research production areas. The biological drug substances are manufactured according to the FDA Guidance for Industry cGMP for Phase I Investigational Drugs, to ensure product safety, identity, purity and strength.

2) Biopathology Center and Center for Childhood Cancer and Blood Diseases
Tour host: Denise Ell, Biopathology Center Research Program Manager and Dr. Ryan Roberts, PI for Childhood Cancer and Blood Diseases, and member of Translational Therapeutics research program at The James Comprehensive Cancer Center at The Ohio State University

The Biopathology Center (BPC) serves as a biorepository for projects sponsored by Nationwide Children’s Hospital investigators as well as a large number of national cancer research consortia. This facility allows for long-term storage of samples, increasing the precision and reliability of research. The BPC is the repository for many National Cancer Institute-sponsored biorepository-based efforts, including the Children’s Oncology Group, the Gynecologic Oncology Group, SWOG (formerly the Southwest Oncology Group), and the Cooperative Human Tissue Network.

The mission of the Center for Childhood Cancer and Blood Diseases is to expand the understanding of the pathogenesis of childhood cancer and to improve strategies for diagnosis and treatment. Areas of focus include:

- Biology and therapy of rhabdomyosarcoma and other childhood tumors
- Chemotherapy of childhood solid tumors
- Regulation of alternative pre-mRNA splicing
- Regulation and function of tumor suppressor genes
- Oncolytic viral therapy in pediatric brain tumors
- Immunotherapy and cellular therapies that harness the natural ability of the immune system to fight cancers
Speakers

Peter C. Adamson, MD

Peter C. Adamson, MD is Chair of the Children’s Oncology Group (COG), a National Cancer Institute (NCI) supported international consortium of more than 220 childhood centers that conducts clinical-translational research, including large-scale clinical trials, in children with cancer. Dr. Adamson is Professor of Pediatrics and Pharmacology at the Perelman School of Medicine of the University of Pennsylvania and holds the Alan R. Cohen Endowed Chair in Pediatrics at Children’s Hospital of Philadelphia (CHOP). He is Board Certified in Pediatric Hematology/Oncology and Clinical Pharmacology. Dr. Adamson serves on the National Cancer Advisory Board (NCAB) and has served as a member of the Blue Ribbon Panel for Vice President Biden’s National Cancer Moonshot Initiative.

Prior to becoming Chair of the COG in 2011, Dr. Adamson was Director for Clinical and Translational Research at The Children’s Hospital of Philadelphia, as well as Chief of the Division of Clinical Pharmacology and Therapeutics. Other past roles include being co-Director of the University of Pennsylvania’s - CHOP Clinical Translational Science Award (CTSA), Program Director of the General Clinical Research Center (GCRC) and Principal Investigator of CHOP’s Pediatric Pharmacology Research Unit (PPRU). His laboratory research focuses on the clinical pharmacology of new drugs for childhood cancer.

Gregory J. Aune, MD, PhD

Dr. Gregory J. Aune is the Stephanie Edlund Distinguished Professor of Pediatric Cancer Research and a St. Baldrick’s Foundation Scholar at the Greehey Children’s Cancer Research Institute in San Antonio, TX. His experience in pediatric cancer spans over 29 years and encompasses his own patient experiences, research in experimental therapeutics, clinical care of pediatric oncology patients, and childhood cancer advocacy. He serves on the National Cancer Institute Council of Research Advocates, the National Cancer Institute Pediatric Leukemia and Lymphoma Steering Committee, and the National Cancer Institute Patient Advocacy Steering Committee.

Amelia Baffa, MSN, APRN, PMHNP-BC

Amelia Baffa has served as the Angie Fowler Adolescent and Young Adult Cancer Nurse Navigator at UH Rainbow Babies & Children’s Hospital (UH-RBC) and the Seidman Cancer Center (SCC) since 2013 to recently. Ms. Baffa is assuming a new role as Psychiatric Mental Health Nurse Practitioner (PMHNP-BC); Coordinator of Pediatric Adolescent & Young Adult Oncology Psychosocial Services at UH-RBC and the SCC, in Cleveland, Ohio. She was awarded the University Hospital Trustee Award for Nursing Excellence and the Red Cross Community Hero Award, in 2015. She was the grant recipient of the Community CureSearch Grant and is the Principal Investigator for a young adult cancer distress study. In 2016 she was awarded a scholarship from Teen Cancer America to become one of the first nurses in the US to attend Coventry University (UK), Teenage and Young Adult Cancer, Post-Graduate Certification program. In 2018 she graduated from Akron University with a Post-Masters Certificate in PMHNP.

She is currently attending an Integrative Community Psychiatric Fellowship for APRNs at Portage Path Behavioral Health Center in Akron, Ohio, where she serves those with severe mental illness and addiction. Ms. Baffa is keenly interested in helping the PAYA cancer population and those with mental health issues as an active and caring advocate. Her mission is to create a psychosocial model of care complicit with programs and services to support individuals and their families through the course of their cancer experience.
Speakers

John A. Barnard, MD

John A. Barnard, M.D., is chief of Pediatrics at Nationwide Children’s Hospital, president of The Research Institute at Nationwide Children’s and holds the Ann I. Wolfe Endowed Chair in Pediatric Research Leadership. He is chair of the Department of Pediatrics at The Ohio State University College of Medicine, where he is a professor of Pediatrics in the Division of Gastroenterology, Hepatology and Nutrition. He is also a practicing gastroenterologist in the Division of Gastroenterology, Hepatology and Nutrition at Nationwide Children’s. An accomplished physician-scientist, he has authored more than 80 peer-reviewed journal articles, reviews and book chapters and garnered NIH support for more than 2 decades.

As president of The Research Institute, Dr. Barnard is responsible for strategic direction, administration, recruiting, resource allocation and infrastructure design in support of all research activities at Nationwide Children’s.

As chair of the Department of Pediatrics at Ohio State, he offers counsel, mentorship and oversight for clinical and academic activities of the more than 500 full-time faculty members. He also oversees the education of more than 300 medical students, pediatric residents and fellows training at Nationwide Children’s Hospital.

Dr. Barnard has been named among the Best Doctors in America for the past decade and has served as a past president of the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition. He was named the 2018 recipient of the Shwachman Award, NASPGHAN’s highest career honor. Dr. Barnard is currently a member of Ohio’s Third Frontier Commission.

Vickie Buenger, PhD

Vickie Buenger serves as Clinical Professor at the Mays Business School with a joint appointment to the Professional Program for Biotechnology at Texas A&M University. She teaches competitive and cooperative business strategy and project management.

Vickie’s daughter, Erin, fought neuroblastoma for seven years. Since Erin’s death in 2009, Vickie has devoted time and energy to launching the Coalition Against Childhood Cancer (CAC2) on behalf of the many dedicated organizations and individuals striving to make a difference for children with cancer. She currently serves as President of CAC2.

She combines her academic background with her interest in the science and policy of childhood cancer and has spoken before gatherings of scientists, clinicians, regulators, industry representatives, and advocates in the United States and Europe. Vickie also serves as the Board Chair of the Hospice Brazos Valley Living Endowment and on the Executive Committee of the Brazos County Democratic Party. She volunteers as an ordained Elder in the Presbyterian Church-USA.

Timothy P. Cripe MD, PhD, FAAP

Timothy P. Cripe MD, PhD, FAAP is the chief of pediatric hematology, oncology and blood and marrow transplantation at Nationwide Children’s Hospital in Columbus, the Gordon Teter Endowed Chair in Pediatric Cancer at Nationwide Children’s Hospital and a professor of pediatrics at the Ohio State Wexner College of Medicine. He is a leader in the preclinical development and clinical testing of oncolytic virotherapy and immunotherapy for children. He recently served on the FDA advisory committee that recommended approval for CAR T cells in children with relapsed leukemia. He is also the founding host of “This Week in Pediatric Oncology,” a podcast about new advances for childhood cancer.

Dr. Cripe received his undergraduate degree in Biochemistry from Princeton University and his MD and PhD in Genetics from the University of Iowa. He completed his pediatric residency training at the University of Iowa Children’s Hospital and his subspecialty fellowship training in pediatric hematology/oncology from Dana-Farber Cancer Institute/Children’s Hospital, Boston and the University of Colorado/Children’s Hospital, Denver. He was on faculty at the University of Wisconsin-Madison and Cincinnati Children’s Hospital prior to coming to Nationwide Children’s.
Speakers

Steven DuBois, MD, MS

Dr. DuBois completed medical school and pediatric training at the University of California, San Francisco (UCSF). He completed pediatric oncology training at Dana-Farber / Boston Children’s Hospital and obtained a Master of Science in Epidemiology from the Harvard School of Public Health. He is currently an Associate Professor of Pediatrics at Harvard Medical School. He is the Director of Experimental Therapeutics at Dana-Farber / Boston Children’s Cancer and Blood Disorders Center where he leads a program designed to bring new targeted therapies to children with cancer.

Dr. DuBois leads an active clinical and translational research program focused on patients with advanced neuroblastoma and Ewing sarcoma. He conducts clinical trials of novel targeted agents relevant to these diseases, including national phase 1, 2, and 3 clinical trials. He also studies new biomarkers that improve our understanding of the biology of pediatric solid tumors and of the pharmacodynamic effects of targeted therapies.

Dr. DuBois has served on a number of national committees, including the Children’s Oncology Group (COG) Neuroblastoma Steering Committee, COG Bone Tumor Committee, COG Developmental Therapeutics Executive Committee, the American Society of Clinical Oncology (ASCO) Scientific Program Committee, and the US FDA Pediatric Oncology Drugs Advisory Committee (ODAC).

Mariah Forster Olson, BA, MBA

Mariah Forster Olson was diagnosed with neuroblastoma in 1980 at the age of one, with a tumor growing out of her spine, wrapping around part of her heart, and occupying the right side of her chest. She had multiple surgeries and 18 rounds of radiation, but was given a low rate of survival. However, she underwent two years of an experimental chemotherapy protocol, which saved her life. Mariah is very appreciative and blessed to be alive, but as a result of her tumor’s location, the treatments, and being treated in the early eighties, she has many medical conditions and late effects, has had 43 surgeries, and deals with chronic, severe bone, muscle, and nerve pain.

Mariah received a BA in political science and a MBA from the University of Wisconsin-La Crosse, and she lives in La Crosse, Wisconsin with her husband, Troy, and two cats. Due to Mariah’s medical issues, she does not have a “conventional” job; however, she works for nine different cancer nonprofits, is writing a book about her life, and plays the oboe professionally. Mariah leads the survivorship interest group for the Coalition Against Childhood Cancer, and she works with and serves on the Board for the Neuroblastoma Children’s Cancer Society. Mariah also works with and serves on the Wisconsin Leadership Board for the American Cancer Society, and she has been to Washington, D.C. to advocate and lobby for cancer-related legislation through the American Cancer Society Cancer Action Network. Mariah’s work truly fulfills her, and she has learned that by sharing her story, she has the possibility to help others and provide hope, understanding, support, and encouragement to those touched by cancer.

Cynthia A. Gerhardt, PhD

Cynthia A. Gerhardt, Ph.D., is a Professor of Pediatrics and Psychology at The Ohio State University, the Director of the Center for Biobehavioral Health at The Research Institute at Nationwide Children’s Hospital, and recipient of the Janet Orttung-Morrow, MD and Grant Morrow, III, MD Endowed Chair in Pediatric Behavioral Health. Dr. Gerhardt graduated from The Ohio State University with a Bachelor of Science prior to receiving her Ph.D. in clinical psychology from the University of Vermont. She completed a pre-doctoral internship and post-doctoral fellowship at Cincinnati Children’s Hospital Medical Center, where she was a faculty member before joining Nationwide Children’s Hospital in 2003.

Dr. Gerhardt is regarded internationally as an expert in risk and resilience factors associated with family adjustment to stress, particularly life-threatening illnesses like childhood cancer. She has published over 140 papers and book chapters and has received multiple grants from the National Institutes of Health, the American Cancer Society, and other national foundations to support her research. Notably, Dr. Gerhardt contributed to the development of international standards for psychosocial care for families of children with cancer, which have been endorsed by leading organizations around the world. In recognition of her work, she received the Dennis Drotar Distinguished Research Award in 2016 from the American Psychological Association Division 54: Society of Pediatric Psychology. Dr. Gerhardt has been actively involved in the mentoring of students and trainees in her lab for 20 years and was awarded the OSU Department of Pediatrics Outstanding Faculty Mentor in 2018 for excellence in teaching.
Lisa Kearns, MS, MA

Lisa Kearns, MS, MA, is a senior researcher at the NYU School of Medicine Division of Medical Ethics and a member of the division’s Working Group on Compassionate Use and Preapproval Access. CUPA was formed in 2014 to study the ethical issues surrounding non-trial access to investigational drugs and comprises representatives from all stakeholder communities involved in preapproval access. She has spoken and published extensively on state and federal “right to try” legislation and is the deputy chair of the oncology and neurology/psychology committees of the Compassionate Use Advisory Committees (CompAC), panels of bioethicists, patient advocates, and medical experts that advise Janssen Pharmaceuticals on the ethical allocation of its investigational medical products.

Lucas Moreno, MD, PhD

Dr. Lucas Moreno leads the Clinical Trials Unit at Hospital Infanta Universitaria Niño Jesús, Madrid, Spain and has devoted his career to childhood cancer drug development. He is funded by a highly competitive mid-career national government fellowship (Juan Rodés) and is dedicated to early clinical trials in paediatric cancers, with interest in neuroblastoma and biomarker development.

In April 2013, he created the Clinical Research Unit for Paediatric Phase I/II Trials, that focuses on the design and development of first-in-child phase I trials and early clinical trials of molecularly targeted agents and immunotherapeutics. In 4 years, the number of open clinical trials have increased four-fold, from 9 to 35, including 8-first-in-child clinical studies of targeted agents. The Unit currently provides service for early clinical trials in Paediatric Oncology, Haematology, Stem Cell Transplantation and Supportive care and is expanding its portfolio to other Paediatric Specialties.

He is a key opinion leader in neuroblastoma drug development in Europe, chairs the Drug Development group and is member of the Executive Committee of the European Neuroblastoma Network and is member of the Clinical Trials Committee of the ITCC consortium. He is the international Chief Investigator of the randomized phase 2 trial BEACON-neuroblastoma open in 10 European countries for relapsed & refractory neuroblastoma. He has led the development of pharmacodynamic biomarkers for PI3K inhibitors in neuroblastoma which are now ready to be implemented in early clinical trials. He is also invited investigator at the Spanish National Cancer Research Centre (CNIO) and is running several projects in neuroblastoma drug development.

Nilsa C. Ramirez, MD

Nilsa C. Ramirez, MD, is a board certified anatomic pathologist with subspecialty training in gynecologic pathology and expertise in perinatal and obstetrical pathology, as well as in biobanking in the context of adult and pediatric cancer clinical trials. She is the Director of Autopsy Services within the Department of Pathology and Laboratory Medicine at Nationwide Children’s Hospital (NCH) in Columbus, OH. She also directs the Biopathology Center, housed at The Research Institute at NCH, overseeing specimen collection, processing, banking, and distribution efforts. At The Ohio State University (OSU) College of Medicine, she is a professor of Clinical Pathology and an active member of the Translational Therapeutics Program of the OSU Comprehensive Cancer Center.

At this time she is Principal Investigator (PI) of numerous grants, including the Pediatric Division of the Cooperative Human Tissue Network, and contact PI of the NCI-sponsored grants supporting the Biospecimen Banks of the Children’s Oncology Group and SWOG. Dr. Ramirez is the Convenor of Working Group 2 - Biobank and Bioresources of the US Technical Advisory Group to the International Organization for Standardization (ISO) Technical Committee 276 Biotechnology; she also represents the College of American Pathologists (CAP) in that committee. At the CAP she is the advisor of the Biorepository Accreditation Program (BAP) Committee and the Regional Commissioner of the CAP BAP. Dr. Ramirez participates in the Group Banking Committee of the NCI’s Cancer Diagnosis Program where she is an active member of several subcommittees and is a member of the NCI-sponsored Frederick National Laboratory Advisory Committee.

Adam Resnick, PhD

Adam Resnick, PhD, is Co-director of Data Driven Discovery in Biomedicine (D3b) at Children’s Hospital of Philadelphia (CHOP). His research is focused on defining the cell signaling mechanisms of oncogenesis and tumor progression in brain tumors. Dr. Resnick’s research lab studies cell signaling cascades and their alterations in pediatric brain tumors to elucidate the molecular and genetic underpinnings of each tumor in an effort to identify and develop targeted therapies. Dr. Resnick serves as Scientific Chair for several consortia-based efforts, including the Children’s Brain Tumor Tissue Consortium (CBTTC) and Pacific Pediatric Neuro-Oncology Consortium (PNOC), which include more than 20 pediatric hospitals across the globe. As co-director of D3b, Dr. Resnick leads a multidisciplinary team to build and support a scalable, patient-focused healthcare and educational discovery ecosystem on behalf of all children.

Speakers
Finding Your Way

Conference Room ED025

Conference Room ED131

Conference Rooms ED137 and ED138

Campus Pathway Map

Legend:
- Blue Path
- Green Path
- Orange Path
- Yellow Path
- Purple Path
- Parking
- Restroom
- Gift Shop
- Information/Security
- Pharmacy
- Concierge
- Pharmacy
- Doorway
- Elevators
- Emergency
- Hospital Parking Garage
- Hospital Entrance
- Outpatient Care Parking Garage
- Education Center
- Urgent Care
- Urgent Care Parking
- Research Elevators
- Radiology
- All Center
- Family Resources
- Imaging
- Respiratory
- Operating Rooms
- Emergency
- Surgical
- Operating Rooms
- Educational Center

Directions:
- From the Outpatient Care Parking Garage (Exit 5, 28th St.): Follow the Orange Path to the West Path. Take a left through the double doors into the Education Center. You're now at the 1st floor. Follow the signs to the Registration area.
- **Due to hospital construction, the routes may change slightly. If you enter through the Outpatient Care Parking Garage and don’t see an orange sign, just follow the Blue Path to the Education Center.**

Finding Your Way

When your child needs a hospital, everything matters.

Nationwide Children’s
With heartfelt appreciation
...to the Sponsors and Supporters of the
2019 CAC2 Annual Summit

CAC2’s all-volunteer leadership team and diverse members are the heart of the organization and the reason for its continued existence and achievements. CAC2 is especially grateful for its Sponsors who provide grants and its Supporters who provide charitable donations so that CAC2 members can collaborate in designing and implementing initiatives that make a difference in the lives of children and adolescents – and their families – who are impacted by cancer.

Host
Nationwide Children’s Hospital

Presenting Sponsor
Novartis

Program Booklet Sponsor
Northwestern Mutual – The Kemelgor Financial Group

Evening Reception Sponsor
Nationwide Children’s Hospital

Breakfast Sponsor (Day One and Day Two)
Functional Formularies

General Sponsorship
Genentech
Northwestern Indiana Cancer Kids Foundation

Sustaining Supporters of CAC2
Charitable donations of $500
Digital Science & Research Solutions
GlaxoSmithKline Foundation
Steven G. AYA Cancer Research Fund
Steven L. Pessagno

SPECIAL THANKS to Elise Morgan, CAC2 Individual Member, who volunteered her skills and time to design this program booklet for the 2019 CAC2 Annual Summit.
REVOLUTIONIZING CLINICAL NUTRITION
organic whole food feeding tube formulas and oral meal replacements

“Don't eat anything your great-grandmother wouldn't recognize as food.”
~ Michael Pollan

WHICH WOULD YOU CHOOSE FOR YOUR LOVED ONE?

Common ingredients in standard feeding tube formulas:

- Corn Oil
- Sunflower Oil
- Agave
- Corn Syrup
- Fruit Juice Concentrate
- Corn Maltodextrin
- Sucralose
- Soy Protein Isolate
- Fructooligosaccharides
- Carrageenan
- Sodium Caseinate
- Soy Lecithin
- Brown Rice Syrup
- Sugar

[NO EXPLANATION NEEDED]
We believe in more than the big breakthroughs. And more than the next big thing.

We believe in the day-in day-out work of making science happen. And the millions of little victories — and failures — in between the breakthroughs. Because to us, it’s the daily effort of everyday people that changes the future. So we don’t stop. We keep working. Every day.
Leaders in Research and Care

Thank you for choosing Nationwide Children’s Hospital to host the Coalition Against Childhood Cancer 2019 Summit & Annual Meeting. We are proud to highlight our leadership across the field of pediatric cancer care and research, such as:

**The NEXT Consortium**
Leading with over 40 institutions throughout North America.

**In-house Good Manufacturing Practice Facility**
The first pediatric hospital designed to streamline discoveries for the rarest pediatric diseases.

**Cellular Therapies and Immunotherapy**
First grant awarded from Department of Defense for neuroblastoma treatment.

**Institute of Genomic Medicine**
A world leader for pediatric personalized genomic medicine.

**Host Defense Program**
One of the country’s first pediatric-focused programs addressing comprehensive infection prevention and management needs.

CAC2 Thanks
Nationwide Children’s for Sponsoring this Year’s Evening Reception
Together, we’ll create a blueprint to guide your financial life.

Create your financial plan with Northwestern Mutual. From financial planning to investment strategies and business planning, together we’ll design a personalized plan to help you achieve financial security. Who’s helping you build your financial future?

Northwestern Mutual - Columbus
800 Yard St Ste 300
Columbus
(614) 221-5287
columbus.nm.com

© 2019 Northwestern Mutual is the marketing name for The Northwestern Mutual Life Insurance Company (NM), Milwaukee, WI (life and disability insurance, annuities, and life insurance with long-term care benefits) and its subsidiaries. Northwestern Mutual Investment Services, LLC (NMIS) (securities), a subsidiary of NM, broker-dealer, registered investment adviser and member FINRA (www.finra.org) and SIPC (www.sipc.org). Troy B Kemelgor is a General Agent(s) of NM. Managing Partners are not in legal partnership with each other, NM or its subsidiaries. Troy B Kemelgor, is a Registered Representative(s) of NMIS. Troy B Kemelgor, is a Representative of Northwestern Mutual Wealth Management Company®, (NMWMC) Milwaukee, WI (fiduciary and fee-based financial planning services), a subsidiary of NM and federal savings bank. All NMWMC products and services are offered only by properly credentialed Representatives who operate from agency offices of NMWMC.
Novartis proudly joins the Coalition Against Childhood Cancer and the 2019 CAC2 Annual Summit

Your dedication to helping patients with childhood cancer is applauded.

At Novartis, our mission is to discover new ways to improve and extend people’s lives. We use science-based innovation to address some of society’s most challenging health care issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.

We are passionate about what we do and the impact we have on society, especially patients, including those living with childhood cancer. We are Novartis, and we are reimagining medicine.